California Business Networking Group

Global shipments of wearable medical devices will surpass 106 million in 2016, as rising awareness and disposable income continue to influence healthcare decisions. Global wearable medical device revenues are set to touch US$ 23,980.5 million, witnessing a y-o-y growth of 4.8% in 2016 over 2015. 

Increasing prevalence of diseases that require round-the-clock monitoring will continue to ramp up demand for wearable medical devices in 2016. Availability of compact, smartphone-compatible devices is also expected to boost adoption. Although average selling price of these devices is expected to witness a decline in 2016, high price still remains a key constraint for many patients. As technology makes further headway and competition become more intense, wearable medical devices are anticipated to become more affordable in the future.

Wearable monitoring and diagnostic devices will continue to witness the highest demand in 2016, followed by wearable therapeutic medical devices. However, the latter will continue to account for higher revenues, owing to higher average selling price of these devices. Total shipments of wearable therapeutic medical devices are anticipated to reach 38,637,108 in 2016, representing market value worth US$ 14,543.6 Mn. Sleep apnea devices will continue to be the highest-selling wearable therapeutic medical device, with total shipments expected to reach 34,008,685 in 2016.

Request Sample Report @  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-826''>https://www.futuremarketinsights.com/reports/sample/rep-gb-826 

Patient monitoring, home healthcare, and health & fitness will continue to remain the key end use application segments of wearable medical devices in 2016. Demand for wearable medical devices will be strongest in home healthcare segment, with total revenues expected to reach US$ 15,281.5 Mn in 2016. Wearable medical devices are gaining traction in the rapidly growing home healthcare sector, giving care providers and patients access to crucial physiological information.

Clinics will continue to be the leading distribution channel for wearable medical devices in 2016. Clinics will sell US$ 7,717.0 Mn worth of wearable medical devices in 2016, up from US$ 7,348.4 Mn in 2015. Sales will continue to gain traction through online channels, with total revenues expected to reach US$ 4,669.0 Mn, a y-o-y increase of 4.6% in 2016 over 2015.

Request to View TOC @  href=''https://www.futuremarketinsights.com/askus/rep-gb-826''>https://www.futuremarketinsights.com/askus/rep-gb-826

North America will continue to be the largest market, followed by Western Europe and Asia Pacific excluding Japan (APEJ). The North America wearable medical devices market will reach US$ 9,608.7 Mn in 2016, up from US$ 9,143.2 Mn in 2015.

Medtronic plc, Koninklijke Philips N.V., Sonova, and Fitbit Inc. are the leading players in wearable medical device market. Geographical expansion, investment in start-ups and SMEs remains the key business strategy of these players.

Long-term Strategy: FMI projects the global wearable medical devices market to expand at 6.9% CAGR during the forecast period 2016-2026.

The approximately US$ 25 Bn market for benign prostatic hyperplasia prostate treatment is likely to expand at 4.6% CAGR during 2018-2028, according to a recent research report of Future Market Insights (FMI). The report has envisaged steady growth prospects for the revenue of global benign prostatic hyperplasia prostate treatment market through 2028.

The World Population Prospects’ data (2017) projected that the number of individuals aged 60 years and above will double by 2050, and triple by 2100. With such a high pace estimated for the growth of population aged 60 years and above, it is more likely that the prevalence of aging related health conditions will also increase at a considerable pace in the years to come. A high prevalence rate of benign prostatic hyperplasia (BPH) in men, the demand for improved and more effective treatment options continues to increase at a high rate.

Alpha-blockers & Drugs for Lower UTIs Remain Pivotal in Benign Prostatic Hyperplasia Prostate Treatment

The drug treatment has been vital in treating benign prostatic hyperplasia conditions and lower UTIs, which has been attributed to widespread availability of drug-based benign prostatic hyperplasia prostate treatment. This factor, in particular, will play an instrumental role in driving the growth of the benign prostatic hyperplasia prostate treatment market during the forecast period. Drugs will remain the first choice of treatment for benign prostatic hyperplasia.

Benign prostatic hyperplasia increases the risk of other disorders as well. The most common disorder caused due to benign prostatic hyperplasia is lower UTI (urinary tract infection) for which, Alpha-blockers constitute the first line of treatment. However, other drugs are also available in the market, which offer relief from the benign prostatic hyperplasia symptoms. Other drugs include alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs.

Request Sample Report @  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-1664''>https://www.futuremarketinsights.com/reports/sample/rep-gb-1664

Demand for Benign Prostatic Hyperplasia Prostate Treatment Higher in Developed Regions, Patient Pool Expanding Steadily in Developing Markets

Owing to significantly growing prevalence of benign prostatic hyperplasia in North American men, benign prostatic hyperplasia prostate treatment market is expected to witness strong growth within the region, followed by Europe.

Extensive availability of benign prostatic hyperplasia prostate treatments, increasing clinical trials, improving R&D scenario, higher healthcare spending, and favorable government initiatives will continue to assist the growth of the benign prostatic hyperplasia prostate treatment market in developed regions.

On the other side, Asia Pacific’s benign prostatic hyperplasia prostate treatment market is foreseen to witness significant growth, owing to steadily expanding patient pool due in the region.

UroLift System to Revolutionize the Competitive Landscape of Benign Prostatic Hyperplasia Prostate Treatment Market

Teleflex Incorporated’s NeoTract recently launched UroLift® System as a highly effective, least invasive option for benign prostatic hyperplasi

Rapidly improving healthcare infrastructure and reimbursement scenario has been a major booster for the healthcare industry in developing regional markets. With incessantly increasing number of cancer cases, it is more likely that the subsequent demand for a wide range of treatments adopted to treat cancer patients would also remain on a constant rise over the course of coming years.

Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.

A new market research study on global radiation-induced myelosuppression treatment forecasts steady growth for the market in the next few years. Future Market Insights projects a moderate, just-under 4% yearly growth outlook, in 2019 and ahead.

Nutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opporunities for radiation-induced myelosuppression treatment providers.

Request Sample Report @  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-8116''>https://www.futuremarketinsights.com/reports/sample/rep-gb-8116 

Report tracks key factors driving revenue growth of the market -

• Increasing prevalence of cancers

• Early diagnosis, promising improved chances of positive outcomes

• Fostering R&D funds supporting cancer research

• Strong product pipeline

• Bolstering adoption of chemo-radiotherapy in cancer treatment

In the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.

• Myelo001 by Myelo Therapeutics GmbH recently received an FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.

• Mylan NV and Pfizer Inc. also reveived FDA approvals for their recently launched biosimilars - Epogen and Neupogen, and Neulasta respectively.

Patent expiry of originator biologics formulations is creating investment opportunities in biosimilars production – for the operators in radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.

Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the radiation-induced myelosuppression treatment market in the region. North America will reportedly continue to account for over 65% share in the global market value.

New product launches currently mark the top developmental strategy adopted by leading companies competing in the radiation-induced myelosuppression treatment market. A majority of key players are also identified to focus on enhancing their geographical foothold in global radiation-induced myelo

Increasing acceptance of therapeutic nuclear medicines (or radiopharmaceuticals) among industry experts will remain a prominent factor encouraging their adoption. Though associated with a negligible risk factor, radiopharmaceuticals are likely to witness growing recommendation owing to no proven significant adverse effects.

In the backdrop of the growing criticality of a more reliable, safer, and lesser harmful line of treatment for cancers, therapeutic nuclear medicines are being increasingly perceived as the potential treatment for cancer patients. Moreover, consistently surging instances of bone metastases further supports adoption growth, in the therapeutic nuclear medicines market.

Just-under 10% Annual Growth Projected for Radiopharmaceuticals Adoption

A recent market research intelligence by Future Market Insights focuses on the deep-dive evaluation of global therapeutic nuclear medicines landscape, emphasizing the analysis of the most influential factors responsible for surging acceptance of radiopharmaceuticals in treating a range of cancers and a few other chronic conditions.

The study projects robust progress for the global radiopharmaceuticals market in coming years, reportedly driven by remarkable adoption in the treatment of prostate cancer. In 2019, the global demand for therapeutic nuclear medicines is expected to grow at a 9.7% annual rate, and maximum adoption is estimated by cancer research institutes at a global level.

• North America, jointly with Western Europe, represents more than 65% share of the total market value.

• Outpacing developed regional markets, the radiopharmaceuticals market in China and emerging economies across Asia Pacific, Latin America, and Middle East & Africa are slated for higher year on year revenue growth of over 12% in 2019 and ahead.

• China is reportedly the most lucrative market for penetration of therapeutic nuclear medicines, which is attributed to an expanding cancer patient pool in the country and a consistently surging rate of radiopharmaceuticals recommendation.

Request Sample Report @  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-2930''>https://www.futuremarketinsights.com/reports/sample/rep-gb-2930

Top Three Companies Account for More than 87% Market Value Share

A highly consolidated marketplace, global therapeutic nuclear medicines landscape is dominated by Bayer AG that currently accounts for just-under 80% revenue share in market. The top three players include GE Healthcare and Novartis AG other than Bayer, which collectively cover over 87% of the total valuation of radiopharmaceuticals market. While exceptional sales and success rate of Xofigo have been prominently retaining Bayer’s top position in the global market, strategic acquisitions are identified to be the key strategy behind Novartis’ success at a global level.

Thorough assessment of the competitive landscape of global therapeutic medicines market reveals a few prominent developmental strategies adopted by a majority of key companies operating in radiopharmaceuticals landscape –

• Investments in R&D of targeted cancer therapeutics

• Stronger supply chain and more streamlined distribution network

• Improved flagship product sales

• Strategic collaborations with pharma/biopharmaceutical companies

• Contractual relationships with domestic/regional stakeholders

• Strategi

Advancements in laser technologies over the years have contributed to various applications of cosmetic treatments, contributing to the growth of the global photorejuvenation equipment market. Rising technological advancements with an increasing number of skin problem are anticipated to increase the adoption of photorejuvenation equipment globally. According to the latest research by the company, the global photorejuvenation equipment market is anticipated to account for over US$ 3,100 Mn, in terms of value, by 2028 end. The report on photorejuvenation equipment is expected to show significant growth potential with an average Y-o-Y growth rate pegged at 6.3% through 2028.

Global Photorejuvenation Equipment Market: Overview & Analysis

Rising incidence of skin problems leads to scarring. Acne causes major physical changes which include permanent scarring. Furthermore, nearly 85% of people aged between 12 and 24 experience acne. The commonly used non-invasive treatment for acne scarring is laser resurfacing. The effectiveness of photorejuvenation equipment are widely accepted in dermatology for the treatment of a variety of cutaneous conditions. Thus, the rising prevalence of such skin problems is triggering the growth of the global photorejuvenation equipment market over the forecast period.

Request Sample Report@  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-7559''>https://www.futuremarketinsights.com/reports/sample/rep-gb-7559

Manufacturers are adopting strategic approaches in order to increase the product reach in the photorejuvenation equipment market. Increasing demand of photorejuvenation equipment for non-invasive photorejuvenation treatments, with frequent product approvals and advancements in photorejuvenation equipment technology, are further boosting the strategic activities like mergers and collaboration agreements among manufacturers and driving the photorejuvenation equipment market growth. Companies operating in the photorejuvenation equipment market are also continuously focusing on increasing the photorejuvenation equipment reach globally. As a result, they are adopting distribution agreements as an expansion strategy to gain maximum revenue share in the global photorejuvenation equipment market. Furthermore, advancements in laser technologies over the years have contributed to various applications of cosmetic treatments, contributing to the growth of the global photorejuvenation equipment market.

Increasing healthcare spending is an indicator of improvement in the healthcare setting as a whole. Increase in the budget of hospitals would indicate the use of better quality equipment's and thus drive the growth of the global photorejuvenation equipment market. According to the IMF, healthcare spending is expected to increase by over 6% yearly, based on the current GDP forecast.

However, high treatment cost and adverse side effects related to the photorejuvenation equipment may hamper the growth of the global photorejuvenation equipment market. Treatment with photorejuvenation equipment, including surgeries and non-invasive treatments, are associated with high costs making them inaccessible to people in the low middle-income groups. Also, non-invasive treatments with photorejuvenation equipment require a series of sessions to achieve the desired result, which results in a high overall cost of the treatment. Furthermore, the duration of treatment, number of sessions and the cost of treatment depend on the

Multiple-Frequency Bioimpedance Devices to Witness Increasing Adoption Through 2028

Increasing cases of CKD diseases are expected to contribute to the growth of the Bioimpedance devices market throughout the forecast period. Chronic kidney disease (CKD) is a medical condition that can be characterized by gradual loss of kidney function over time. As per the National Kidney Foundation, Inc., 30 million American adults have Chronic Kidney Disease and millions of others are at high risk of developing CKD. The Glomerular filtration rate (GFR) is the best overall index for studying kidney function. Bioelectrical impedance or Bioimpedance is used for improved estimation of glomerular filtration rate in non-diabetic patients with chronic kidney disease and also to estimate muscle mass. Bioelectrical impedance analysis (BIA) can also be used to measure appendicular lean mass (ALM). The performance of these equations that include ALM BIA to estimate renal inulin clearance (GFR INU) can be compared with demographic variables and further used for modifications in diet for renal disease (MDRD) treatment.

Widespread online marketing channels have tremendously increased the sale of portable as well as hand-held Bioimpedance devices in recent years. For Instance, a research study estimated that in 2015, approximately 70% of the population in the U.S. depended on online shopping portals for buying different items. Vendors operating in the Bioimpedance devices market are focusing on promotional strategies and online marketing to ensure better access to their devices and increase sales. Devices offered online also help vendors cut on operational and distribution costs. The online marketing channel also allows vendors to offer information about devices in their portfolio and gain access to both global and local markets. In addition, these online marketing websites provide a broad selection of high-quality Bioimpedance systems at more affordable costs.

Request Sample Report @  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-5563''>https://www.futuremarketinsights.com/reports/sample/rep-gb-5563 

Majority of the manufacturers in the Bioimpedance Devices makers are focusing on developing products that are portable and affordable. The popularity of portable Bioimpedance devices is increasing due to its various advantages. For instance, Bioimpedance Devices are noninvasive, reasonable, safe and easy to operate. These devices are light in weight and thus, are extensively used in home-based healthcare settings for monitoring health of the entire family. All these factors, cumulatively, are expected to drive the demand for portable Bioimpedance devices during the forecast period. Portable/ Hand-held Bioimpedance devices are also tremendously being opted by people for traveling purposes. For instance, the demand for ImpediMed SFB7, which is a hand-held Bioimpedance device, is increasing as this device is easy to carry. Technological advancements to enhance the quality of Bioimpedance devices and increase patient compliance are also projected to drive the growth of the market over the forecast period.

Multiple-frequency Bioimpedance Devices are highly preferred because these devices can measure impedances in various frequencies. This provides a better and efficient estimation of fat free mass, total body water and intra and extra cellular water. Single frequency Bioimpedance devices can calculate fat free mass and total body water but these devices are not capable of estimating intra and extra cellular body water. Increasing popularity and growing awareness abou

The approximately US$ 1.3 billion market for airway management devices is likely to observe a sluggish pace over next few years, presumably crossing the revenue of US$ 1.5 Bn towards 2022 end. Around half of the market value share is accounted by North America, according to the report.

A senior research analyst at the company says, ''The well-known complications and contraindications associated with the use of airway management devices continue to restrict adoption of airway management device types. The subsequent safety concerns are thus leading to frequent product recalls, resulting in the limited growth potential of airway management device landscape at a global level''.

Explaining the market dynamics further, the analyst says, ''The companies are however extending strong efforts towards adapting their products to evolving regulatory guidelines and thereby boosting new product launches. While preventing product recalls will remain in the focal point for manufacturers of airway management devices, they continue to primarily witness sustained demand for anesthesia administration''.

Request Sample Report @  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-7775''>https://www.futuremarketinsights.com/reports/sample/rep-gb-7775 

Pre-hospital Settings Are Increasingly Demanding ‘Safer’ Single Use Airway Management Devices

With decently growing demand for emergency medical services and trauma management, the pre-hospital airway management is constantly becoming an imperative segment. With a primary objective to prevent the risks of cross infection, pre-medical settings are generating consistently growing demand for disposable laryngeal masks. While these airway management devices allow easy insertion and curtail the chances of gastric aspiration, it is more likely that single use airway management devices will witness steady revenue growth in coming years.

FMI Highlights Opportunities for Pediatric Airway Management Devices Manufacturers

In an effort to facilitate the otherwise challenging pediatric airway management, manufacturing companies leading the airway management devices landscape are incorporating an extensive range of cutting-edge technologies in existing devices. The FMI report indicates a chunk of lucrative opportunities residing in the pediatric airway management segment.

• The Classic Laryngeal Mask Airway (LMA) is currently witnessing notable traction owing to its exceptional efficiency in terms of attaining ventilation in children.

• The Proseal LMA is likely to enjoy notable adoption in coming years.

• Recently, Smith Medical launched Protex Bivona FlexTend TTS tracheostomy tubes exclusively for newborns, further covering pediatric patients in the company’s flagship product line.

The FMI analyst also says, “While the airway management space has been witnessing the successful introduction of next-generation endo-bronchial tubes equipped with camera, there is a strong likelihood of fostered product demand for thoracoscopic lung surgeries as well as in robotic surgeries. This and more such technological innovations can potentially uplift the revenue growth scenario of airway management devices market in coming years”.

Segmentation Analysis by FMI at a Glance

• EndoBronchial tubes hold over 40% share of the current market value, followed by laryngeal masks, reveals the airway management devices market analysis by the type of product. Nasal airway tubes are

Increasing incidence of eye diseases such as cataract and refractive errors coupled with rising number of eye care clinics and hospitals globally are factors increasing the adoption of next generation optical biometry devices. With the advancement in the technology, next generation optical biometry devices have been developed aiding measurement of eyes before cataract and refractive surgeries. Earlier measurement by ultrasound technique was gold standard. However, unlike next generation optical biometry devices, ultrasound devices require direct contact of the probe, which lead to many eye infections.

The next generation optical biometry devices are automated and measure many parameters such as the axial length, anterior chamber depth, thickness of the lens, retinal thickness, pupil size and many more. The next generation optical biometry devices are an accurate alternative for the precise measurements and provide efficient results. Also the next generation optical biometry devices avoid the operator variations measurements.  Research indicates next generation optical biometry devices market is anticipated to account for revenues over US$ 450 Mn, by 2028 end. The report on next generation optical biometry devices projects market revenues to expand at a CAGR of 5.1% through 2028.

A Sample Of This Report Is Available Upon Request @  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-7556''>https://www.futuremarketinsights.com/reports/sample/rep-gb-7556

According to Prevent Blindness organization, ~25 Mn Americans having cataract require medical care every year in the U.S., hence boosting demand for next generation optical biometry devices. Similar rising demand for next generation optical biometry devices is noted in UK with rising number of cataract surgeries. Increased demand for next generation optical biometry devices is noted in developing markets concurrent with access to eye care facilities. Next generation optical biometry devices are all-in one devices used for evaluation of lens and refraction, of retina.

Next Generation Optical Biometry Devices Market: Overview & Analysis

Rapid increase in number of probe infections due to usage of ultrasound devices, lead to post-operative errors fuelling demand for next generation optical biometry devices instead of ultrasound biometry devices. Manufacturers of next generation optical biometry devices are introducing automated devices which are more efficient in measuring segments of eyes. Players in next generation optical biometry devices market are working on strengthening the software, which could provide detailed information about eye segments. New next generation optical biometry devices introduced are taking into account irregularities and astigmatisms of the anterior and the posterior surfaces of the eye. The next generation optical biometry devices uses a partially coherent wave that has approximately 9x the resolution of a 10 MHz sound wave, for precise measurement of axial length.

Hospitals end users segment account for 41.8% revenue share in the global Next Generation Optical biometry Devices market. Medical services and vision benefits offered under Medicare includes cataract surgeries; which will increase the demand of next generation optical biometry devices.

Increasing geriatric population and rising income in Japan is expected to surge the demand for more advanced Next Generation Optical biometry Devices. Japan Next Generation Optica

A new Future Market Insights’ study on the global sales scenario for point of care cholesterol monitoring devices projects just-under 3% year over year revenue growth for the market estimated to cross US$ 400 million in 2019.

Increasing CVD prevalence and a growing number of high-cholesterol cases are sustaining the demand for point of care cholesterol monitoring device worldwide. Although a growing patient population is maintaining a decent consumption rate of point of care cholesterol monitoring devices, high per test cost and tightening regulatory norms regarding medical devices launch continue to limit adoption.

FMI Analyses Key Pull Factors Translating into the Sluggish Revenue Growth of Point of Care Cholesterol Monitoring Device Market

Recently in 2017, FDA approved the SD LipidoCare System launched by SD Biosensor Inc. However, a majority of medical device manufacturers continue to face the challenges to new product launch as a set of certain evolved amendments recently designed by regulatory policies target the lack of standardization across their device portfolios. Local medical device manufacturers exclusively encounter the impediments posed by regulatory-linked issues.

More importantly, the inaccuracy of results delivered by point of care cholesterol monitoring devices still persists that makes the entire procedure less reliable and riskier. This continues to linger as a major concern restraining revenue growth of point of care cholesterol monitoring device market.

Request Sample Report @   href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-7773''>https://www.futuremarketinsights.com/reports/sample/rep-gb-7773

Global Point of Care Cholesterol Monitoring Device Market Taxonomy: By Product Type, Technology Type, Application Type, End User, and Region

• According to the product type analysis of point of care cholesterol monitoring device market presented in the report, testing kits are currently more popular but instruments, especially computerized, are gradually gaining ground among end users and thus end use segments.

• The technology type analysis of point of care cholesterol monitoring device market reveals that both the key technologies, i.e. electrochemical biosensor and reflectance photometry currently hold an almost equal share of the market revenue. The overall growth is however sluggish.

• Based on the application type analysis, the point of care cholesterol monitoring device market is likely to witness maximum demand for atherosclerosis patients, whereas sales of point of care cholesterol monitoring devices in the hypercholesterolemia segment is also considerable.

• End user analysis offered in the point of care cholesterol monitoring device market report uncovers considerable product consumption by diagnostic centers, diagnostic laboratories, hospitals, and ambulatory surgical centers. Lucrative adoption prospects for point of care cholesterol monitoring devices have been indicated in home care settings.

• While more than 1/3^rd of the global market revenue belongs to North America, Western Europe and APECJ remain the next two key markets for point of care cholesterol monitoring devices. The report forecasts attractive product innovation and penetration opportunities arising in MEA and Latin America for manufacturers.

A Growing Self-testing Trend Boosts Point of Care Cholesterol Monitoring

Expanding at a rather modest annual growth rate of 4.6 percent, the global market for oxycodone is projected to reach a revenue of US$ 4 Billion in 2028—showcasing an absolute dollar opportunity of US$ 181.3 Mn, through 2018-2019. Future Market Insights, in its recent analysis of the global oxycodone market, elaborates on the key market dynamics, opportunity assessment, and regional and competitive landscape analysis, for a period spanning 2018 to 2028.

With nearly 10-fold increase in the use of opioids since its inception, the oxycodone contributes to one of the largest revenue generator in the overall pharmaceutical landscape. Intensifying sales of oxycodone can be attributed to:

Increasing patent expirations for branded products and much lesser new product launches, translating into increased consumption of generics—that contribute to the maximum revenue of the global oxycodone market, thereby, fueling the net sales.

Request Sample Report@  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-7638''>https://www.futuremarketinsights.com/reports/sample/rep-gb-7638

Growing number of cancer treatments, which in turn, increases the demand for supportive care medications for pain management. Increased prescriptions of oxycodone and Hydrocodone for treating cancer pain, will remain the largest contributor to the sales growth of the aforementioned medication.

“In terms of demand, high efficiency of synthetic and semi-synthetic opioids increase its use. In addition, Opioids prescription is highly regulated by a set of clinical practice guidelines, while ensuring safe access and proper dosage. Opioids are covered under such stringent regulations translates into increased consumption. Rising awareness about palliative care in terminal disease conditions combined with favorable reimbursement policies are some additional demand-side factors, augmenting the consumption of opioids”, projects a senior analyst at FMI

Elaborating further, the analyst explains that palliative care programs in US—which includes palliative care consultation teams and dedicated in-patient palliative care units—are delivered in accordance with the government and commercial reimbursement policies, further boosting the oxycodone market in the region. In addition to palliative programs, increased prescription in de-addiction programs, is well contributing to the demand of de-addiction opiates.

Innovative Drug Formulations Pushing Oxycodone Global Sales

In the in-depth analysis of the oxycodone market, FMI underlines the introduction of innovative opiate drugs, currently occupying a lion’s share. Innovations in formulations—not necessarily targeted at drug efficacy— is a critical supply-side driver in the global oxycodone market. Abuse-deterrent formulations in Oxycontin, by Purdue Pharma is one such example. Moreover, Purdue has been granted exclusive selling rights for Oxycontin till 2030, after it made formulations changes to the drug’s chemical structure, thereby marketing it as an ‘abuse-proof’, slow-releasing pill. In addition, FDA’s nod to new generation drugs, making them ‘less-addictive’, will gain prominence through 2028. Drug advancements in extended-release medications for pain control, would supplement to the sales of oxycodone, globally. This scenario

A US-based team of researchers has recently developed a microfluidic device for isolating a genomic DNA, which is to be purified later. This DNA is sourced from individual cells and the device physically catches single cells using a micropillar array. It also captures chromosomal DNA of these single cells post-extraction, which is later immobilized in the micropillar array so as to enable the process of isothermal amplification. The entire methodology is referred to as ‘on-chip cell capture and DNA extraction’. As conventional single cell WGA is often prone to amplification biases, which may hold a significant influence on the accuracy of the data of single cell sequencing. This drawback is foreseen to be overcome with the introduction of single cell on-chip WGA, resulting in reduced biases regarding amplification, offering an improved coverage of the genome. The team has used individual cancer cell genomes (human), sourced from the HeLa Cell Line.

WGA has been a crucial procedure that helps in DNA analysis from limited quantities of genomic DNA. The ease provided by various WGA kits available for the entire process has been driving the market over the years. Increasing research activities will remain the key factor pushing the growth of whole genome amplification market over the next decade. Adoption of this process is expected to witness robust growth, predominantly among research institutes, hospitals, diagnostic centers, and forensic labs, as it offers an improved and advanced means of genome amplification and sequencing.

Request Sample Report@  href=''https://www.futuremarketinsights.com/reports/sample/rep-gb-1873''>https://www.futuremarketinsights.com/reports/sample/rep-gb-1873

To increase the revenue share, molecular testing companies are focusing more on the development of advanced devices and kits such as WGA kits and complete WGA kits with advanced capabilities. The global whole genome amplification market is estimated at around US$ 4 million by the end of 2028, as indicated by a recent report released by Future Market Insights. The global market for whole genome amplification will possibly expand at a CAGR of 7.7% during the forecast period, 2018-2028.

Single Cell WGA Continues to Bring in New Applications

Introduction of massively parallel single-cell genome sequencing is anticipated to offer a new dimension to the understanding of genetic diversities in complex biological systems. Single cell WGA is a method used to examine the sequence information with the optimized next generation sequencing technologies, only from a single cell. This method is considered to be a powerful tool that helps to understand the ins and outs of genetics by bringing the entire genome structure to a cellular level. Since this method offers a high-resolution view of the genomic sample, its adoption will continue to be on the rise in diverse biological fields such as microbiology, immunology, neurobiology, cancer research, and tissue mosaicism. Single cell WGA also plays a crucial role in conveying new applications to the market, eventually pushing the market growth further through 2028.

New Technology Assessment in Branded WGA Products

As a move towards better results and implementation of advanced technology, novel techniques are being introduced in the new WGA products. The TruePrime Single Cell WGA Kit (Expedeon Ltd.), utilizes a unique and reliable method to achieve accurate genome amplification from single cells. TruePrime technology uses a revolutionary novel multiple displacement amplification (MDA) method base